| P50 | author | Jingchuan Guo | Q49794743 |
| P2093 | author name string | Haiyan Li | |
| | Glenn F Carlson | |
| | Renli Teng | |
| P2860 | cites work | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics | Q26822796 |
| | Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update | Q27006031 |
| | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin | Q28195019 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry | Q33447413 |
| | Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers | Q34019342 |
| | Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 |
| | Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study | Q34021458 |
| | Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects | Q34120974 |
| | Platelet function tests: a comparative review | Q35121464 |
| | The growing complexity of platelet aggregation | Q36740902 |
| | Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine | Q37465914 |
| | Polymorphism of human cytochrome P450 enzymes and its clinical impact | Q37514326 |
| | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist | Q37552005 |
| | Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes | Q37959155 |
| | Cytochrome P450 variations in different ethnic populations | Q37979866 |
| | Racial/ethnic differences in drug disposition and response: review of recently approved drugs | Q38351175 |
| | Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study | Q38479485 |
| | Long-term use of ticagrelor in patients with prior myocardial infarction | Q40263764 |
| | Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy | Q42910350 |
| | Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects | Q43187673 |
| | Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. | Q45954831 |
| | Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. | Q46707933 |
| | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE | Q46916592 |
| | In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics | Q48302970 |
| | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. | Q50468521 |
| | Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? | Q53388110 |
| | Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. | Q54580627 |
| | Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. | Q54790334 |
| | [Guideline for diagnosis and treatment of patients with chronic stable angina (no abstract)] | Q80507634 |
| | Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment | Q85167435 |
| | Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers | Q87730194 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 352-361 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease | |
| P478 | volume | 82 | |